Novosibirsk · Russian-qualified counsel Recognised by Pravo-300 · Best Lawyers · Kommersant
Cross-border Disputes

A practical guide to corporate disputes in Russian commercial courts in the pharmaceuticals sector

Vitaliy Vetrov · September 2026 · 13 min read

Foreign pharmaceutical companies face complex corporate disputes in Russian courts. A step-by-step guide from Russian counsel. Make an enquiry.

Unlike procedural regimes in many European jurisdictions, Russian commercial court litigation does not consolidate regulatory and civil claims in a single forum. For foreign pharmaceutical companies operating in Russia — whether through a direct subsidiary, a joint venture, or a distribution structure — corporate disputes commercial Russia proceedings unfold across several distinct arenas, each with its own filing rules, timelines, and evidentiary standards. Understanding that architecture before a dispute crystallises is the practical prerequisite for protecting the company's position under Russian law pharmaceuticals frameworks.

What to prepare before proceedings begin

Before engaging Russian counsel on a live corporate dispute in Russian commercial courts pharmaceuticals context, in-house counsel should assemble the following:

The mandatory pre-trial claim requirement is a critical procedural threshold for most corporate disputes in Russian commercial courts. Russian procedural rules require claimants to send a formal written claim to the respondent and allow a statutory waiting period — typically 30 calendar days — before filing proceedings. Failure to satisfy this requirement results in the claim being returned without consideration. For pharmaceutical companies managing supply-chain disputes or distributor terminations under time pressure, this is not a formality to be resolved retrospectively.

Step 1 — Assess the dispute and identify the correct forum

Corporate disputes commercial Russia proceedings are heard in the system of arbitrazh courts — the specialised commercial courts that handle disputes between legal entities and individual entrepreneurs. General civil courts (courts of general jurisdiction) do not have jurisdiction over commercial disputes between corporate entities. Foreign companies and their Russian subsidiaries therefore direct their claims to the relevant arbitrazh court, typically the arbitrazh court of the subject of the Russian Federation (region) in which the respondent has its registered address.

Within the arbitrazh court system, several specialist tracks are relevant to the pharmaceuticals sector:

The first is standard commercial litigation — breach of contract, recovery of debt, supply disputes, and distributor termination claims. These are handled by the arbitrazh court at first instance.

The second is intellectual property and registration disputes — invalidity challenges to patents, trade mark disputes, and challenges to registration decisions by Roszdravnadzor affecting marketing authorisations. Patent validity and trade mark registration matters proceed through the IP Court (Suд по интеллектуальным правам), a specialist federal court. Disputes involving the administrative decisions of federal regulators — including Roszdravnadzor — are typically heard in the arbitrazh court for the Moscow Region or the Moscow City Arbitrazh Court, depending on the authority's registered location.

The third track is antitrust and competition disputes, relevant where a foreign pharmaceutical company faces a Federal Antimonopoly Service (FAS Russia) investigation into pricing conduct, market dominance, or distribution restrictions. Challenges to FAS decisions are heard by the arbitrazh court in the district where the FAS office issued the contested decision.

For foreign companies considering arbitration clauses in future contracts with Russian counterparties, the availability of the Russian Arbitration Centre (RAC) and MKAS at the Russian Chamber of Commerce and Industry should be assessed against the specific dispute type. State court jurisdiction cannot be excluded by agreement for certain categories of corporate dispute, including challenges to the validity of decisions of the general meeting of a Russian company.

If you are assessing forum options for a corporate dispute with a Russian pharmaceuticals counterparty, our cross-border disputes practice can advise on jurisdiction and procedural strategy. Make an enquiry: info@vetrovpartners.com |

Step 2 — Build the pre-litigation position

The quality of the position a foreign company enters litigation with is largely determined by steps taken in the weeks before filing. Russian court foreign claimant positions are often weakened not by the underlying merits but by incomplete procedural groundwork.

Four elements are particularly significant:

First, the pre-trial claim (претензия) must be substantively complete — not a pro forma notice. It should state the legal basis for the claim, the amount sought (where quantifiable), and a defined response deadline. Courts review the content of the претензия at the admissibility stage, and a claim that is materially vague may not satisfy the pre-trial requirement even if it was sent on time.

Second, any contractual limitation periods must be tracked against the statutory backdrop. The general limitation period under Russian civil law is three years. For certain categories of pharmaceutical distribution and supply contracts, shorter contractual periods may apply. Creditors who delay initiating enforcement proceedings risk losing their statutory window in circumstances where the Russian counterparty files for insolvency independently — at which point the foreign company becomes a creditor in the insolvency estate rather than a claimant in commercial proceedings, with materially different recovery mechanics.

Third, interim relief — in particular, asset preservation orders (обеспечительные меры) — should be assessed at this stage. Russian arbitrazh courts have jurisdiction to grant interim relief in support of a pending or imminent claim. The threshold for obtaining such relief is demonstrable risk that the respondent will dissipate, conceal, or encumber the assets in dispute before a judgment can be enforced. Applications must be filed alongside or immediately after the statement of claim and supported by documentary evidence. The procedural window for applying is narrow: once the counterparty is on notice of proceedings, asset movements become harder to prevent through court order alone.

Fourth, secure a complete extract from the Unified State Register of Legal Entities (EGRUL) for the respondent company. This document, available from the Federal Tax Service portal, confirms current ownership, registered address, authorised capital, and any outstanding administrative proceedings — all facts that bear on the merits and enforcement prospects of the claim.

Step 3 — Does the pharmaceuticals regulatory context affect your dispute?

For foreign pharmaceutical companies, corporate disputes in Russian commercial courts pharmaceuticals proceedings frequently involve a regulatory dimension that has no direct equivalent in Western European commercial litigation. Three regulatory intersections are most commonly encountered:

Marketing authorisation and distribution rights. Disputes with Russian distributors often involve the question of who controls the marketing authorisation (государственная регистрация лекарственного средства) issued by the Ministry of Health. Where a distributor holds the registration in its own name — a structure that arose particularly in older distribution arrangements — the termination of the distribution agreement does not automatically transfer or extinguish the registration. Foreign companies seeking to repatriate distribution rights must address the regulatory position in parallel with the commercial dispute. This typically requires separate engagement with the Ministry of Health and may involve administrative proceedings before the arbitrazh court.

Parallel import and trade mark enforcement. Following changes to Russian intellectual property rules, parallel import of certain pharmaceutical products became permissible under a government-approved list. Foreign trade mark owners seeking to challenge parallel importation of their pharmaceutical products in Russian courts must navigate the intersection of trade mark law, the approved parallel import list, and Roszdravnadzor's quality certification requirements. A claim that succeeds on trade mark grounds may nonetheless fail to restrain the parallel imports if the regulatory authorisation for those specific batches is separately upheld. Coordinated litigation strategy — addressing both the commercial and regulatory dimensions — is therefore the standard approach in these matters.

FAS Russia pricing investigations. In the pharmaceuticals sector, which includes a government-regulated list of vital and essential medicines (ЖНВЛП), pricing conduct is subject to heightened FAS Russia scrutiny. A foreign company engaged in commercial disputes with a Russian counterparty — including disputes arising from contract termination — may find that the counterparty initiates a parallel FAS complaint as a tactical measure. Managing the FAS proceedings and the commercial litigation simultaneously, with a consistent factual narrative across both forums, requires co-ordination between litigation and regulatory counsel.

For in-house counsel managing a Russian subsidiary in the pharmaceuticals sector, the regulatory timeline leaves limited margin for sequential decision-making. Regulatory authorisations have their own renewal and lapse cycles, and a contested distribution arrangement that is left unresolved while commercial proceedings run their course may result in a lapsed authorisation that materially affects the subsidiary's ability to operate.

For guidance on the interaction between Russian pharmaceuticals regulation and commercial litigation strategy, contact our cross-border disputes team: info@vetrovpartners.com |

Step 4 — Initiate proceedings and manage the procedural sequence

Once the pre-litigation position is established and forum is confirmed, proceedings are initiated by filing a statement of claim (исковое заявление) with the relevant arbitrazh court. The document must satisfy formal requirements set out in the Russian Arbitration Procedure Code: identification of the parties, statement of the factual basis, legal qualification of the claims, and specification of the relief sought. Evidence relied upon must be attached at the time of filing — the practice of serving disclosure after proceedings commence, familiar from English litigation, does not apply in Russian commercial court procedure.

Courts operate on a case management track system. At first instance, straightforward commercial disputes between legal entities are typically determined within three to six months of filing. Disputes involving regulatory elements — for example, challenges to FAS decisions or disputes touching on Roszdravnadzor authorisations — commonly extend to nine to twelve months at first instance, given the volume of administrative materials that must be placed before the court. These timelines are general estimates; actual duration varies by circuit, case complexity, and court workload. The Moscow arbitrazh courts, which handle the majority of disputes involving foreign pharmaceutical companies, have historically carried heavier caseloads than regional courts, which can extend first-instance timelines.

Appeals proceed through a defined sequence: the appellate arbitrazh court (апелляционный суд) hears appeals on both fact and law within the same circuit. Cassation review is conducted by the circuit arbitrazh court (кассационный суд); a further cassation by the Supreme Court's Economic Panel (Коллегия по экономическим спорам) is available but not automatic — it requires a separate petition and is granted selectively.

Foreign claimants should engage Russian-qualified legal counsel before filing, not after. The arbitrazh courts do not make procedural accommodations for foreign parties who are unfamiliar with the requirements. Procedural errors at the filing stage — including deficiencies in powers of attorney for foreign counsel, translation requirements for foreign-language documents, and the form of legalisation or apostille — result in claims being left without movement (оставление без движения) and a court-imposed deadline for correction. Missing that deadline results in the claim being returned, which may have limitation period consequences if the original filing was made at the last available moment.

See also our Regulatory Update: Corporate Disputes in Russian Commercial Courts for recent developments in procedural requirements affecting foreign claimants.

Step 5 — How do enforcement and post-judgment strategy work in Russian commercial courts?

Obtaining a judgment is the beginning of the enforcement process, not the end of it. For foreign pharmaceutical companies that have litigated to a favourable decision in a Russian arbitrazh court, the enforcement pathway involves the following sequence:

A writ of execution (исполнительный лист) is issued by the court upon the judgment becoming enforceable. The writ is presented to the Federal Bailiff Service (Федеральная служба судебных приставов, FSSP), which opens enforcement proceedings. The FSSP has statutory timeframes for taking enforcement steps — identifying and seizing assets, directing banks to freeze accounts, and realising pledged or attached property — but in practice the pace of proceedings varies materially depending on the nature and location of assets and the responsiveness of the debtor.

Where the respondent is a Russian legal entity with identifiable bank accounts, direct bank account enforcement — presenting the writ directly to the debtor's bank — is often more efficient than FSSP enforcement and can produce results within days rather than weeks. This requires knowledge of the debtor's banking relationships, which is why pre-litigation EGRUL and corporate intelligence work (Step 2) is directly relevant to enforcement strategy.

Where the judgment debtor has insufficient Russian assets, or where the dispute involves cross-border recovery across Russia and another EAEU or CIS member state, the recognition and enforcement of the Russian judgment in the relevant foreign jurisdiction must be assessed separately. Russia's bilateral treaty arrangements and the Minsk and Kishinev Conventions govern enforcement within the EAEU and CIS framework — a route that is procedurally more straightforward than enforcement in jurisdictions without a treaty basis.

For a broader view of cross-border enforcement strategy in Russian commercial disputes, see Corporate Disputes in Russian Commercial Courts: A Foreign Law Firm's Guide and our Matters page for representative completed engagements.

If you have obtained or are anticipating a judgment in Russian commercial proceedings and need to assess enforcement options, our team can advise on FSSP strategy, direct bank enforcement, and cross-border recovery. Discuss your matter in confidence: info@vetrovpartners.com |

Frequently asked questions

Q: How long does a corporate dispute in a Russian commercial court typically take from filing to first-instance judgment?

A: For standard commercial disputes between legal entities — supply contract claims, distributor terminations, and debt recovery — the first-instance arbitrazh court commonly reaches judgment within three to six months of filing. Disputes with a regulatory dimension, such as those involving challenges to Roszdravnadzor decisions or FAS Russia conduct investigations, extend this to nine to twelve months or more at first instance. The appellate stage typically adds a further three to four months. These are general estimates; actual duration varies by circuit and case volume. The Moscow arbitrazh courts, which handle most matters involving foreign pharmaceutical companies, tend to run on the longer end of these ranges given their caseload.

Q: What documents does a foreign pharmaceutical company need to file a claim in a Russian arbitrazh court?

A: The core filing package comprises the statement of claim (исковое заявление), all contractual and correspondence evidence relied upon, proof that the mandatory pre-trial claim (претензия) was sent and the waiting period has elapsed, and a document confirming the claimant's legal status — typically the company's certificate of incorporation or equivalent, properly legalised or apostilled and translated into Russian by a certified translator. Where the claimant is acting through a representative, a formally executed power of attorney is required; for foreign companies, this document must also be legalised and translated. Failure to attach any required document at the time of filing results in the claim being left without movement, with a short court-set deadline for correction.

Q: What happens if the Russian counterparty files for insolvency after commercial proceedings have been initiated?

A: If insolvency proceedings are opened against the respondent after the commercial claim has been filed but before judgment, the commercial proceedings are typically suspended, and the claimant's claim is redirected into the insolvency estate as a creditor's claim. The foreign company must file a creditor's claim with the insolvency manager within the statutory period from publication of the insolvency decision — missing this deadline results in the claim being relegated to a less favourable creditor class. Where insolvency is filed after a judgment has been obtained but before enforcement is complete, the judgment debt is enrolled in the creditor register. This is why pre-litigation interim relief and early enforcement steps — direct bank account enforcement and FSSP proceedings — are strategically significant: they can secure priority recovery before insolvency displaces the commercial proceedings entirely.

Practitioner note

This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.

Facing a matter like this?

Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.

Make an enquiry